Abnormal liver biochemistry constitutes an independent prognostic factor of a less favorable clinical course in patients with COVID-19
| Autor: | Alventosa Mateu C, Urquijo Ponce JJ, Puchades Gimeno F, Benlloch Pérez S, Sanz Herrero F, Latorre Sánchez M, García Deltoro M, Gimeno Cardona C, Ocete Mochón MD, Diago Madrid M |
|---|---|
| Rok vydání: | 2021 |
| Zdroj: | Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia instname |
| ISSN: | 1130-0108 |
| Popis: | INTRODUCTION: Abnormal liver biochemistry (ALB) is correlated with increased clinical involvement or severity in COVID-19, but its prognostic implications have not been studied extensively. Our aim is to determine whether ALB is a risk factor for an unfavorable clinical outcome and involvement. MATERIALS AND METHODS: Retrospective, single-center study of confirmed COVID-19 cases. Patients with pharmacological hepatotoxicity or liver diseases were excluded. ALB was defined as the elevation of total bilirubin, AST, ALT, alkaline phosphatase and/or GGT above the upper limit of normal. An assessment was first made of the correlation between ALB and the need for hospitalization. This was followed by an assessment of the correlation of hospitalized patients with demographic variables, comorbidities and treatment for COVID-19 and with clinical involvement and outcome. Statistical analysis was performed using age-adjusted multiple logistic regression with a p-value of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|